Number of NDA of innovative drugs approved in China 2018-2021
In 2021, the Center for Drug Evaluation of the National Medical Products Administration (NMPA) in China approved 69 New Drug Applications (NDA) for innovative drugs, with more than half of all approvals granted to chemical drugs. A New Drug Application (NDA) is the mechanism through which pharmaceutical manufacturers propose that the regulatory body approve a new drug or biopharmaceutical for general use and sale.